Search for α1-adrenoceptor subtypes selective antagonists: Design, synthesis and biological activity of cystazosin, an α(1D)-adrenoceptor antagonist

Bioorganic and Medicinal Chemistry Letters

Volumn 8, Issue 11, 1998, Pages 1353-1358

  Minarini, Anna ^a   Budriesi, Roberta ^a   Chiarini, Alberto ^a   Leonardi, Amedeo ^b   Melchiorre, Carlo ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b Recordati SpA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

8 [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] 8 AZASPIRO[4.5]DECANE 7,9 DIONE; ALPHA 1 ADRENERGIC RECEPTOR; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 1D ADRENERGIC RECEPTOR; CYCLAZOCINE; CYSTAZOSIN; PRAZOSIN; QUINAZOLINE DERIVATIVE; RECEPTOR SUBTYPE; UNCLASSIFIED DRUG;

ANIMAL TISSUE; AORTA; ARTICLE; BINDING AFFINITY; DRUG BINDING; DRUG DESIGN; DRUG MECHANISM; DRUG STRUCTURE; DRUG SYNTHESIS; NONHUMAN; RAT; SPLEEN; STRUCTURE ACTIVITY RELATION; VAS DEFERENS;

ADRENERGIC ALPHA-ANTAGONISTS; ANIMALS; AORTA, THORACIC; BINDING, COMPETITIVE; DRUG DESIGN; HUMANS; MALE; QUINAZOLINES; QUINOXALINES; RATS; RECEPTORS, ADRENERGIC, ALPHA-1; RECEPTORS, SEROTONIN; RECEPTORS, SEROTONIN, 5-HT1; SPLEEN; STRUCTURE-ACTIVITY RELATIONSHIP; VAS DEFERENS;

EID: 0032474531     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(98)00217-0     Document Type: Article

References (34)

1. 1. (a) Bylund, D. B.; Eikenberg, D. C.; Hieble, J. P.; Langer, S. Z.; Lefkowitz, R. J.; Minneman, K. P.; Molinoff, P. B.; Ruffolo, R. R., Jr.; Trendelenburg, U. Pharmacol. Rev. 1994, 46, 121.
2. (b) Hieble, J. P.; Bylund, D. B.; Clarke, D. E.; Eikenburg, D. C.; Langer, S. Z.; Lefkowitz, R. J.; Minneman, K. P.; Ruffolo, R. R., Jr. Pharmacol. Rev. 1995, 47, 267.
3. 2. Michel, A. D.; Loury, D. N.; Whiting, R. L. Br. J. Pharmacol. 1989, 98, 883.
4. 3. García-Sáinz, J. A.; Romero-Avila, Ma. T.; Tórres-Márquez, Ma. E. Eur. J. Pharmacol. (Mol. Pharmacol. Section) 1995, 289, 81.
5. 4. Eltze, M.; Boer, R.; Sanders, K. H.; Kolassa, N. Eur. J. Pharmacol. 1991, 202, 33.
6. 5. Testa, R.; Guarneri, L.; Ibba, M.; Strada, G.; Poggesi, E.; Taddei, C.; Simonazzi, I.; Leonardi, A. Eur. J. Pharmacol. 1993, 249, 307.
7. 6. Han, C.; Abel, P. W.; Minneman, K. P. Nature 1987, 329, 333.
8. 7. Aboud, R.; Shafii, M.; Docherty, J. R. Br. J. Pharmacol. 1993, 109, 80.
9. 8. Testa, R.; Destefani, C.; Guarneri, L.; Poggesi, E.; Simonazzi, I.; Taddei, C.; Leonardi, A. Life Sci. 1995, 57, PL 159.
10. 9. Faure, C.; Pimoule, C.; Arbilla, S.; Langer, S. Z.; Graham, D. Eur. J. Pharmacol.-Mol. Pharmacol. Sect. 1994, 268, 141.
11. 10. Ford, A. P. D. W.; Williams, T. J.; Blue, D. R.; Clarke, D. E. Trends Pharmacol. Sci. 1994, 15, 167.
12. 1L-adrenoceptors and are characterized by a low functional affinity for prazosin. However, these receptors have not been cloned yet and their characterization is still difficult. See: Testa, R.; Guarneri, L.; Angelico, P.; Poggesi, E.; Taddei, C.; Sironi, G.; Colombo, D.; Sulpizio, A. C.; Naselsky, D. P.; Hieble, J. P.; Leonardi, A. J. Pharmacol. Exp. Ther. 1997, 281, 1272.
13. 12. (a) Kenney, B.; Ballard, S.; Blagg, J.; Fox, D. J. Med. Chem. 1997, 40, 1293.
14. (b) Leonardi, A.; Testa, R.; Motta, G.; De Benedetii, P. G.; Hieble, P.; Giardinà, D. In Perspective in Receptor Research; Giardinà, D., Piergentili, A., Pigini, M., Eds.; Elsevier: Amsterdam, 1996; pp 135-152.
15. (c) Ruffolo, R. R., Jr.; Bondinell, W.; Hieble, J. P. J. Med. Chem. 1995, 38, 3681.
16. 13. Goetz, A. S.; King, H. K.; Ward, S. D. C.; True, T. A.; Rimele, T. J.; Saussy, D. L., Jr. Eur. J. Pharmacol. 1995, 272, R5.
17. 14. Giardinà, D.; Brasili, L.; Gregori, M.; Massi, M.; Picchio, M. T.; Quaglia, W.; Melchiorre, C. J. Med. Chem. 1989, 32, 50.
18. 15. Giardinà, D.; Gulini, U.; Massi, M.; Piloni, M. G.; Pompei, P.; Rafaiani, G.; Melchiorre, C. J. Med. Chem. 1993, 36, 690.
19. 16. Giardinà, D.; Crucianelli, M.; Romanelli, R.; Leonardi, A.; Poggesi, E.; Melchiorre, C. J. Med. Chem. 1996, 39, 4602.
20. 17. Melchiorre, C. Trends Pharmacol. Sci. 1981, 2, 209.
21. 18. NMR spectra (Varian VXR 300 instrument) were registered for all compounds and supported the assigned structures. For the synthesis of 2-5, the experimental procedures were similar to those described in detail in ref 14 for the corresponding carbon analogues, namely 1,6-hexanediamine derivatives.
22. 19. Devisky, F.; Lacko I.; Krasnec, L. Synthesis 1980, 303.
23. 20. These compounds were purified as oils by flash silica column chromatography eluting with petroleum ether-ethyl acetate-methanol-40% ammonia (4:4:1:0.1) and used in the next step without further purification.
24. 2·HCl) C, H, N.
25. 22. Eltze, M.; Boer, R. Eur. J. Pharmacol. 1992, 224, 125.
26. 23. Eltze, M. Eur. J. Pharmacol. 1994, 260, 211.
27. 24. Teng, C.-M.; Guh, J.-H.; Ko, F.-N. Eur. J. Pharmacol. 1994, 265, 61.
28. 25. (a) Arunlakshana, O.; Schild, H. O. Br. J. Pharmacol. 1959, 14, 48.
29. (b) Tallarida, R. J.; Cowan, A.; Adler, M. W. Life Sci. 1979, 25, 637.
30. 26. (a) Fargin, A.; Raymond, J. R.; Regan, J. W.; Cotecchia, S.; Lefkowitz, R. J.; Caron, M. G. J. Biol. Chem. 1989, 284, 14848.
31. (b) Fargin, A.; Raymond, J. R.; Lohse, M. J.; Kobilka, B. K.; Caron, M. G.; Lefkowitz, R. J. Nature 1988, 335, 358.
32. 27. De Lean, A.; Munson, P. J.; Rodbard, D. Am. J. Physiol. 1978, 235, E97.
33. 28. Cheng, Y. C.; Prusoff, W. H. Biochem. Pharmacol. 1973, 22, 3099.
34. 29. Testa, R.; Taddei, C.; Poggesi, E.; Destefani, C.; Cotecchia, S.; Hieble, J. P.; Sulpizio, A. C.; Naselsky, D.; Bergsma, D.; Ellis, C.; Swift, A.; Ganguly, S.; Ruffolo, R. R.; Leonardi, A. Pharmacol. Commun. 1995, 6, 79.